Full-Time
Global Operations Leadership Development Program
Gold
Updated on 8/17/2026
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
No salary listed
No H1B Sponsorship
Horsham, PA, USA + 20 more
More locations: Shepherdsville, KY, USA | Mooresville, IN, USA | Spring House, PA, USA | New Brunswick, NJ, USA | Irvine, CA, USA | Raritan, NJ, USA | Santa Clara, CA, USA | Wilson, NC, USA | Cornelia, GA, USA | Malvern, PA, USA | Memphis, TN, USA | Somerset County, NJ, USA | Plymouth, MN, USA | San Angelo, TX, USA | Hopewell Township, NJ, USA | Jacksonville, FL, USA | Irving, TX, USA | Athens, GA, USA | Danvers, MA, USA | Cincinnati, OH, USA
Hybrid
Hybrid role with geographic flexibility across the United States; relocation packages are provided for moves exceeding 50 miles.
Bachelor's
 Operations & Logistics (1) |
|---|
Get referred to Johnson & Johnson
See people who can refer or advise you
- Permanent United States work authorization is required now and in the future; the company does not provide sponsorship for employment visas.
- A minimum bachelor's degree from an accredited university or college in supply chain, business administration, business management, data science, or engineering is required, with the degree earned between December 2022 and June 2027.
- An overall cumulative GPA of 3.4 or higher is required, subject to the stated waiver for qualifying internal full-time Johnson & Johnson employees.
- A minimum of four months of professional experience in a relevant business area is required by December 31, 2026; qualifying areas include supply chain, operations, logistics, engineering, quality, data analytics, information systems, research and development, or a directly related field.
- Applicants must have United States geographic flexibility throughout the program and through final placement.
- Applicants must be eligible to begin full-time employment no later than June 2027; optional February-April 2027 start dates may be offered to applicants who earned a bachelor's degree by December 2026.
- Demonstrate a working knowledge of how Johnson & Johnson's global supply chain functions connect to support the business and customers.
- Participate in the planning, production, and distribution of products and services.
- Maintain or improve manufacturing operational cost, efficiency, capacity, and compliance.
- Collaborate with internal customers and external vendors to drive key business decisions and outcomes.
- Learn about designing or redesigning new products.
- Maintain quality and regulatory compliance.
- Understand the impact of the business on the customer experience.
- Keep the customer at the center of work activities.
- Rapidly learn, evaluate, and adopt new artificial intelligence tools and platforms to meet evolving project needs.
- Complete rotational assignments across multiple United States sites and participate in business, leadership, and personal development training.
- Build technical capabilities across project management, supply chain management, quality and regulatory compliance, manufacturing operations, customer and logistics services, and product and process analysis and improvement methodologies.
- Interest in exploring multifunctional assignments across a global supply chain.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
- TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
- The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.
What critics are saying
- Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
- The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
- A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.
What makes Johnson & Johnson unique
- J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
- TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
- TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -2%The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.
Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.
Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.
Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.
Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.